RET and medullary thyroid gland carcinoma: In a phase 1-2 study of selpercatinib in patients with progressive RET-mutant MTC a 69% response rate was seen in patients who had previously received vandetanib or cabozantinib with a 73% response rate in TKI-naïve patients (33).